Dr. Kamaljit Kaur is an Associate Professor of Targeted Drug Delivery and Biomedical Diagnostics at the School of Pharmacy of Chapman University.
Dr. Kaur received her PhD (1999) in Bioorganic Chemistry from Case Western Reserve University, Cleveland, Ohio, where the topic of her thesis was low density lipoprotein (LDL) oxidation. Following her Ph.D., she accepted a postdoctoral position at Wesleyan University (Connecticut), where she worked on design of antibacterial agents targeted toward penicillin resistant bacteria. She accepted a second postdoctoral position in the Department of Chemistry at the University of Alberta to work on antimicrobial peptides. Subsequently Dr. Kaur joined the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta (Edmonton, Canada) as an Assistant Professor, and was tenured and promoted to an Associate Professor in 2012. In 2015, she joined Chapman University to lead a globally acclaimed research program in Targeted Drug Delivery and Biomedical Diagnostics.
During her academic career, Dr. Kaur has taught several courses in medicinal chemistry, drug delivery and bioanalytical techniques at the undergraduate and graduate levels. She has served on the review panel of several granting agencies, such as Canadian Institutes of Health Research (CIHR) and Canadian Breast Cancer Foundation (CBCF) and has served as a reviewer for more than 25 journals. She has published 47 peer reviewed articles, 3 book chapters, been listed as an inventor in 1 approved patent, and has presented 20 invited talks.
Dr. Kaur’s research has evolved into two main programs:
(i) Targeted Drug Delivery
Her research program in “Targeted Drug Delivery” involves engineering cancer targeting peptides for increased therapeutic efficacy of current chemotherapeutic drugs, and development of peptide-drug conjugates (PDCs).
(ii) Biomedical Diagnostics
Her research program in “Biomedical Diagnostics” involves design, synthesis, and development of peptide-based biosensor platforms as diagnostics for pathogenic bacteria and circulating tumor cells.
R. Soudy, C. Chen, and K. Kaur*, Novel Peptide-Doxorubicin Conjugates for Targeting Breast Cancer Cells including the Multidrug Resistant Cells, J. Med. Chem.,2013, 56, 7564-7573.
R. Soudy, A. Gill, T. Sprules, A. Lavasanifar, and K. Kaur*, Proteolytically Stable Cancer Targeting Peptides with High Affinity for Breast Cancer Cells, J. Med. Chem., 2011, 54, 7523-7534.
S. Ahmed, A.S. Mathews, N. Byeon, A. Lavasanifar, K. Kaur*, Peptide Arrays for Screening Cancer Specific Peptides. Anal. Chem.,2010, 82, 7533-7541.
S. Azmi, K. Jaing, T. Thundat, K. Kaur*, Detection of Listeria monocytogenes with short peptide fragments from class IIa bacteriocins as recognition elements, ACS Comb. Sci.,2015, 17, 156-163.
H. Etayash, K. Jaing, T. Thundat, K. Kaur*, Impedimetric Detection of Pathogenic Gram-Positive Bacteria using An Antimicrobial Peptide from Class IIa Bacteriocins, Anal. Chem., 2014, 86, 1693-1700.
R. Soudy, L. Wang, and K. Kaur*, Synthetic Peptides derived from the Sequence of a Lasso Peptide Microcin J25 show Antibacterial Activity, Bioorg. Med. Chem., 2012, 20, 1794-1800.